Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant ...
Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...
Zacks Investment Research on MSN
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
Insulet Corporation PODD reported third-quarter 2025 adjusted earnings per share (EPS) of $1.24, up 37.8% from the year-ago ...
If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...
The Case: Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Dexcom, Inc. securities during the class period because the Company ...
Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...
Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
Kirby McInerney LLP reminds investors who purchased DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) securities to contact Thomas W. Elrod of Kirby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback